Catalyst Wire Dossier Catalyst Wire Dossier

N8-GP (Turoctocog alfa pegol)

turoctocog alfa pegol · Novo Nordisk A/S
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for N8-GP (Turoctocog alfa pegol), covering 2024-01-18 to 2024-01-18. Get the full timeline:

Most recent: Clinical Trial Update: Efficacy and Safety of Turoctocog Alfa Pegol (N8-GP) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (pathfinder10) [Phase 3]

See pricing